Relación entre COVID-19 con el desarrollo de enfermedades autoinmunes
Relationship of COVID-19 with the development of autoimmune diseasesContenido principal del artículo
En la actualidad existe un gran número personas diagnoticadas con SARS-CoV-2, llamando la atención la aparición de algunas enfermedades de origen autoinmunes post exposición a esta infección. Se cree que su asociación está dada por mecanismos que incluyen el mimetismo molecular, los autoanticuerpos y la estimulación de la señalización inflamatoria. Objetivo. Identificar la relación entre COVID-19 con el desarrollo de enfermedades autoinmunes. Metodología. Se realizó una revisión sistemática de la literatura, donde, se utilizó buscadores científicos en la siguiente base de datos: Pubmed, Cocharne, Scielo y Science Direct. La búsqueda de información estuvo comprendida entre 2020 al 2022, se utilizaron palabras claves y algoritmo de búsqueda con la combinación de términos: “COVID-19”, “enfermedades autoinmunes”, “autoinmunidad”, además de esto se utilizaron operadores booleanos “And”, “Or” y “Not” con la finalidad de obtener mejores resultados en la brusquedad. Conclusión. Los principales mecanismos involucrados en el desarrollo de autoinmunidad posterior a la infección por SARS-CoV-2 incluye el mimetismo molecular, la presencia de autoanticuerpos y la tormenta de citoquinas propias de la infección por COVID-19. Las enfermedades de carácter autoinmune con las que se estableció relación directa: Síndrome de Guillan-Barré, Encefalitis autoinmune, Enfermedad de Graves, Tiroiditis de Hashimoto, Purpura trombocitopenica autoinmune y Vasculitis, además también se consideró la Enfermedad similar a Kawasaki - like, Lupus Eritematoso Sistémico, mismas que aún necesitan de más estudios para establecer con exactitud su mecanismo de acciones con relación a la infección de SARS-CoV-2.
Currently there are a large number of people diagnosed with SARS-CoV-2, drawing attention to the appearance of some diseases of autoimmune origin after exposure to this infection. It is believed that their association is given by mechanisms that include molecular mimicry, autoantibodies and stimulation of inflammatory signaling. Objective. To identify the relationship between COVID-19 and the development of autoimmune diseases. Methodology. A systematic review of the literature was carried out, using scientific search engines in the following database: Pubmed, Cocharne, Scielo and Science Direct. The information search was carried out from 2020 to 2022, using keywords and search algorithm with the combination of terms: "COVID-19", "autoimmune diseases", "autoimmunity", in addition to this, Boolean operators "And", "Or" and "Not" were used in order to obtain better results in the abruptness. Conclusion. The main mechanisms involved in the development of autoimmunity following SARS-CoV-2 infection include molecular mimicry, the presence of autoantibodies and the cytokine storm characteristic of COVID-19 infection. The autoimmune diseases with which a direct relationship was established are: Guillan-Barre syndrome, autoimmune encephalitis, Graves' disease, Hashimoto's thyroiditis, autoimmune thrombocytopenic purpura and vasculitis, in addition to Kawasaki-like disease, systemic lupus erythematosus, which still need further studies to establish their exact mechanism of action in relation to SARS-CoV-2 infection.
Descargas
Detalles del artículo
Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview. Eur J Pharmacol. 2020 15; 889:173644. doi: 10.1016/j.ejphar.2020.173644.
Marcuzzi A, Melloni E, Zauli G, Romani A, Secchiero P, Maximova N, et al. Autoinflammatory Diseases and Cytokine Storms-Imbalances of Innate and Adaptative Immunity. Int J Mol Sci. 2021 18;22(20):11241. doi: 10.3390/ijms222011241.
Tan LY, Komarasamy TV, Rmt Balasubramaniam V. Respuesta inmune hiperinflamatoria y COVID-19: una espada de doble filo. inmunol frontal. 2021; 12:742941. doi: 10.3389/fimmu.2021.742941.
Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021; 7; 31:100683. doi: 10.1016/j.eclinm.2020.100683.
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi: 10.21203/rs.3.rs-266574/v1.
Knight JS, Caricchio R, Casanova JL, Combes AJ, Diamond B, Fox SE, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131(24): e154886. doi: 10.1172/JCI154886.
Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898-907. doi: 10.1111/cts.12953.
Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7): 2095-7.doi: 10.1007/s10067-020-05180-7.
Ishay Y, Kenig A, Rubin L, Shamriz O, Kharouf F. Autoimmune Diseases Induced or Exacerbated by COVID-19: A Single Center Experience. Autoimmune Dis. 2022;2022: 9171284.doi: 10.1155/2022/9171284.
Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19(5): 102524.doi: 10.1016/j.autrev.2020.102524.
Spierings J, Sloeserwij A, Vianen ME, de Boer JH, Sigurdsson V, van de Wijgert JHHM, et al. Health-related quality of life in patients with immune mediated inflammatory diseases: A cross-sectional, multidisciplinary study. Clin Immunol. 2020;214: 108392.doi: 10.1016/j.clim.2020.108392.
Mobasheri L, Nasirpour MH, Masoumi E, Azarnaminy AF, Jafari M, Esmaeili SA. SARS-CoV-2 triggering autoimmune diseases. Cytokine. 2022;154: 155873.doi: 10.1016/j.cyto.2022.155873.
Yazdanpanah N, Rezaei N. Autoimmune complications of COVID-19. J Med Virol. 2022;94(1):54-62. doi: 10.1002/jmv.27292.
Houen G, Trier NH, Frederiksen JL. Epstein-Barr Virus and Multiple Sclerosis. Front Immunol. 2020; 11:587078. doi: 10.3389/fimmu.2020.587078.
Miller IF, Becker AD, Grenfell BT, Metcalf CJE. Disease and healthcare burden of COVID-19 in the United States. Nat Med. 2020;26(8):1212-17. doi: 10.1038/s41591-020-0952-y.
Pérez AMR, Gómez TJJ, Dieguez GRA. Características clínico-epidemiológicas de la COVID-19. Revista Habanera de Ciencias Médicas. 2020;19 (2):1-15. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2020000200005&lng=es.
Hanaei S, Rezaei N. COVID-19: Developing from an Outbreak to A Pandemic. Arch Med Res. 2020;51(6):582-4. doi: 10.1016/j.arcmed.2020.04.021.
Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021;29(1):20-36. https://infezmed.it/media/journal/Vol_29_1_2021_3.pdf
Jimeno-Almazán A, Pallarés JG, Buendía-Romero Á, Martínez-Cava A, Franco-López F, Sánchez-Alcaraz Martínez BJ, et al. Post-COVID-19 Syndrome and the Potential Benefits of Exercise. Int J Environ Res Public Health. 2021;18(10):5329. doi: 10.3390/ijerph18105329.
Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4):102792. doi: 10.1016/j.autrev.2021.102792.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-8. doi: 10.1007/s00134-020-05991-x.
Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17-41. doi: 10.1002/JLB.3COVR0520-272R.
Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature. J Autoimmun. 2021; 117:102592. doi: 10.1016/j.jaut.2020.102592.
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17): e38. doi: 10.1056/NEJMc2007575.
Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-daté systematic review of 73 cases. J Neurol. 2021;268(4):1133-70. doi: 10.1007/s00415-020-10124-x.
Tang KT, Hsu BC, Chen DY. Manifestaciones autoinmunes y reumáticas asociadas con COVID-19 en adultos: una revisión sistemática actualizada. inmunol frontal. 2021: 645013. doi: 10.3389/fimmu.2021.645013.
Siracusa L, Cascio A, Giordano S, Medaglia AA, Restivo GA, Pirrone I, Saia GF, Collura F, Colomba C. Neurological complications in pediatric patients with SARS-CoV-2 infection: a systematic review of the literature. Ital J Pediatr. 2021;47(1):123. doi: 10.1186/s13052-021-01066-9.
Payus AO, Jeffree MS, Ohn MH, Tan HJ, Ibrahim A, Chia YK, Raymond AA. Immune-mediated neurological syndrome in SARS-CoV-2 infection: a review of literature on autoimmune encephalitis in COVID-19. Neurol Sci. 2022;43(3):1533-47. doi: 10.1007/s10072-021-05785-z.
Tutal E, Ozaras R, Leblebicioglu H. Systematic review of COVID-19 and autoimmune thyroiditis. Travel Med Infect Dis. 2022; 47:102314. doi: 10.1016/j.tmaid.2022.102314.
Nabizadeh F, Balabandian M, Sodeifian F, Rezaei N, Rostami MR, Naser Moghadasi A. Autoimmune encephalitis associated with COVID-19: A systematic review. Mult Scler Relat Disord. 2022; 62:103795. doi: 10.1016/j.msard.2022.103795.
Carrillo-Larco RM, Altez-Fernandez C, Ravaglia S, Vizcarra JA. COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. Wellcome Open Res. 2020; 5:107. doi: 10.12688/wellcomeopenres.15987.2.
Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-62. doi: 10.1097/BOR.0000000000000776.
Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D, Alijotas-Reig J, Zinserling V, Semenova N, Amital H, Shoenfeld Y. Covid-19 and autoimmunity. Autoimmun Rev. 2020;19(8):102597. doi: 10.1016/j.autrev.2020.102597.
Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G. New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. Cells. 2021;10(12): 3592.doi: 10.3390/cells10123592.
Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol. 2021;40(7):2611-9. doi: 10.1007/s10067-021-05691-x.
Murugan AK, Alzahrani AS. El SARS-CoV-2 juega un papel fundamental en la inducción del hipertiroidismo de la enfermedad de Graves. Endocrino. 2021; 73 (2): 243-54. doi: 10.1007/s12020-021-02770-6.
Talotta R, Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J Clin Cases. 2020;8(17):3621-44. doi: 10.12998/wjcc. v8. i17.3621.
Makhluf H, Madany H. Infección por SARS-CoV-2 y síndrome de Guillain-Barré. Patógenos. 2021; 10 (8): 936. doi: 10.3390/pathogens10080936.
Ruggeri RM, Campennì A, Deandreis D, Siracusa M, Tozzoli R, Petranovi? Ov?ari?ek P, Giovanella L. Trastornos tiroideos inmunoinflamatorios relacionados con el SARS-COV-2: hechos y perspectivas. Experto Rev Clin Immunol. 2021; 17 (7): 737-59. doi: 10.1080/1744666X.2021.1932467.
Al-Beltagi M, Saeed NK, Bediwy AS. COVID-19 disease and autoimmune disorders: A mutual pathway. World J Methodol. 2022;12(4):200-23. doi: 10.5662/wjm. v12.i4.200.
Murugan AK, Alzahrani AS. SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases. J Inflamm Res. 2021; 14:6191-221. doi: 10.2147/JIR.S332705.